Capital Initiative

Endosense is a medical technology company dedicated to enhancing the efficacy, safety, and consistency of catheter ablation procedures used to treat cardiac arrhythmias. The company developed the TactiCath, the first and only force-sensing ablation catheter that provides physicians with a real-time and objective measure of contact force during ablation. The TactiCath received the CE mark in May 2009 and has undergone extensive pre-clinical and clinical testing, establishing a strong evidence base for the feasibility and safety of contact force sensing in catheter ablation. Endosense's innovations aim to improve patient outcomes and streamline ablation procedures in the field of cardiology.

Xigen SA is a private biopharmaceutical company based in Switzerland, established in 2002 as a spin-off from the University Hospital of Lausanne. Led by Dr. Christophe Bonny, a prominent molecular biologist with extensive research experience in intracellular peptides and signaling, Xigen specializes in the development of innovative therapeutic peptides aimed at addressing inflammation. The company's peptides are characterized by their metabolic stability and specificity, allowing for selective delivery to intracellular targets through proprietary carrier molecules. This unique approach enables the treatment of a wide array of diseases, positioning Xigen as a key player in the biopharmaceutical industry.

Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company based in Geneva, Switzerland, specializing in the discovery, development, and commercialization of novel orally available small-molecule drugs, particularly allosteric modulators targeting central nervous system (CNS) disorders. The company's leading programs include Dipraglurant, aimed at treating levodopa-induced dyskinesia in Parkinson's disease and dystonia, ADX71149 for epilepsy and other undisclosed CNS disorders, and a GABAB positive allosteric modulator for addiction. Addex Therapeutics emphasizes the advantages of allosteric modulators over traditional non-allosteric molecules, as they may provide improved therapeutic solutions. The company also has a collaboration agreement with Janssen Pharmaceuticals Inc. to develop mGluR2PAM compounds for therapeutic use. Founded in 2002, Addex Therapeutics was formerly known as Addex Pharmaceuticals Ltd and rebranded in March 2012.

Dartfish SA is a company that specializes in video solutions aimed at enhancing performance across various sectors, including sports, education, healthcare, and industry. Founded in 1999 and headquartered in Fribourg, Switzerland, Dartfish offers a range of products designed for capturing, analyzing, and sharing video content. Key offerings include myDartfish, a personal workspace for skill analysis; myDartfish Express, which identifies areas for athlete improvement; and myDartfish Smart Cloud, a secure platform for storing and sharing video assets. Additionally, Dartfish provides ProSuite for automatic tracking of video annotations, Dartfish Connect for combining video with notes, and tools for live video analysis. The company also operates Dartfish.tv, a video sharing site that enhances video content with features like special effects. With a global presence, including offices in the United States, Europe, Asia, and Australia, Dartfish is recognized for its innovative contributions to video technology and has received multiple awards for its work in the field.